Cystic Fibrosis Diagnosis by Analyzing Nasal Brushing (MUCO-BROCC)
Primary Purpose
Cystic Fibrosis, Atypical Form of Cystic Fibrosis
Status
Unknown status
Phase
Not Applicable
Locations
France
Study Type
Interventional
Intervention
Nasal brushing
Sponsored by
About this trial
This is an interventional diagnostic trial for Cystic Fibrosis focused on measuring Cystic fibrosis, Adults, Atypical form, Nasal brushing, Epithelial cells, Ion transport
Eligibility Criteria
Inclusion Criteria:
For patients with cystic fibrosis and those with atypical form:
• Inclusion at least 30 days after a general or local infection of the upper airways
For controls:
• No history or Sino-pulmonary pathology and negative identification of mutations in the CFTR gene
For all subjects involved in research:
- Information and obtaining informed consent of the subjects.
- Age ≥ 18 years
- affiliation to a social security scheme or of such a regime
Exclusion Criteria:
For all participants :
- Taking a per os corticoids or topical corticosteroid treatment in the nose in the month preceding the nasal brushing or measurement of nasal potential difference
- ORL surgical history of under 2 months
- cauterization of the inferior turbinate of under 2 months
- Hypersensitivity to local anesthetics of the amide (such as lidocaine) or with one of the components, including methyl parahydroxybenzoate contained in the excipient.
- Porphyria.
- Epilepsy not controlled by treatment.
Sites / Locations
- Centre Hospitalier Intercommunal de CréteilRecruiting
Arms of the Study
Arm 1
Arm Type
Other
Arm Label
Diagnostic test
Arm Description
Diagnostic test will be perform on cell from nasal brushing
Outcomes
Primary Outcome Measures
Quality of the CCBN test
The primary endpoint is composite. The diagnostic quality of the test CCBN is the analysis of nasal epithelial cells:
in basal short-circuit current,
in amiloride-sensitive current corresponding to ENaC
cyclic AMP-dependent current corresponding to CFTR
Secondary Outcome Measures
Nasal potential difference
The nasal potential difference will be evaluated :
in basal,
after infusion of a solution of amiloride,
after infusion of a solution without amiloride chloride,
after infusion of a solution of amiloride and isoproterenol (agonist of cAMP).
Full Information
NCT ID
NCT02433132
First Posted
April 29, 2015
Last Updated
September 27, 2017
Sponsor
Assistance Publique - Hôpitaux de Paris
1. Study Identification
Unique Protocol Identification Number
NCT02433132
Brief Title
Cystic Fibrosis Diagnosis by Analyzing Nasal Brushing
Acronym
MUCO-BROCC
Official Title
Study of Ion Transport From Nasal Epithelial Cells Collected by Brushing (CCBN) in the Diagnosis of Atypical Forms of Cystic Fibrosis
Study Type
Interventional
2. Study Status
Record Verification Date
September 2017
Overall Recruitment Status
Unknown status
Study Start Date
March 2015 (undefined)
Primary Completion Date
July 2018 (Anticipated)
Study Completion Date
September 2018 (Anticipated)
3. Sponsor/Collaborators
Responsible Party, by Official Title
Sponsor
Name of the Sponsor
Assistance Publique - Hôpitaux de Paris
4. Oversight
Data Monitoring Committee
No
5. Study Description
Brief Summary
The diagnosis of CF is currently based on the discovery of two CFTR gene mutations and / or a positive sweat test (> 60mmol / l). A significant number of patients with atypical cystic fibrosis (chronic sino-pulmonary disease with a single mutation in the CFTR gene and / or a test of the intermediate sweat between 30 and 60 mmol / l) undetected by these techniques are behind specialized care while irreversible lung damage is already existed. Currently, the measurement of nasal potential difference in vivo (DPN), which evaluates the transportation of chlorine in the nasal epithelium with an electrode, is proposed for the diagnosis of atypical forms. However DPN dependent nasal local conditions when analysing do not always offer the possibility of concluding the diagnosis of cystic fibrosis. It is necessary to develop new and more reliable diagnostic tests for the detection of cases of atypical cystic fibrosis. The authors propose to develop a new diagnostic technique based on the study of bioelectric properties of a preparation of nasal cells of the subject obtained by brushing and placed in primary culture (CCBN).
Detailed Description
Autosomal recessive, CF is caused by mutations in the CFTR gene whose nature determines the clinical expression and severity of the disease affecting mainly the respiratory, digestive and genital. Respiratory pathology is mainly responsible for the morbidity and mortality of patients with cystic fibrosis. CFTR, which is ion channel carrying chlorine, plays an essential role in respiratory disease through its involvement in the changes of surface liquid covering the respiratory epithelial cells.
Currently the measurement of nasal potential difference in vivo (DPN) can cause arguments electrophysiological diagnosis of cystic fibrosis (chlorine transport default) for patients with atypical form but can be rendered difficult or non-interpretable by the lack of cooperation of the patient (especially in the children who do not support the presence of the probe into the nose) or mostly due to poor local conditions related to infectious diseases rhino sinus of these patients.
It is necessary to develop new and more reliable diagnostic tests for the detection of cases of atypical cystic fibrosis. The study of ion transport from nasal epithelial cells collected by brushing (NBC) in the diagnosis of atypical forms of cystic fibrosis is tested in this trial as a new diagnostic test.
This research will focus on three groups:
Of patients with cystic fibrosis adults.
adult patients with atypical form
people who do not have cystic fibrosis
Depending on the patient group, there will be only one CCBN or CCBN and DPN or CCBN and DPN and genetic analysis to verify the absence of mutation.
6. Conditions and Keywords
Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Cystic Fibrosis, Atypical Form of Cystic Fibrosis
Keywords
Cystic fibrosis, Adults, Atypical form, Nasal brushing, Epithelial cells, Ion transport
7. Study Design
Primary Purpose
Diagnostic
Study Phase
Not Applicable
Interventional Study Model
Single Group Assignment
Masking
None (Open Label)
Allocation
N/A
Enrollment
128 (Anticipated)
8. Arms, Groups, and Interventions
Arm Title
Diagnostic test
Arm Type
Other
Arm Description
Diagnostic test will be perform on cell from nasal brushing
Intervention Type
Other
Intervention Name(s)
Nasal brushing
Intervention Description
The CCBN test is to evaluate the ion transport in the nasal epithelial cells taken from a subject by brushing the inferior turbinate with a mini-brush after local anesthesia. Analysis of ion transport is carried out ex vivo on the primary culture of nasal epithelial cells after brushing
Primary Outcome Measure Information:
Title
Quality of the CCBN test
Description
The primary endpoint is composite. The diagnostic quality of the test CCBN is the analysis of nasal epithelial cells:
in basal short-circuit current,
in amiloride-sensitive current corresponding to ENaC
cyclic AMP-dependent current corresponding to CFTR
Time Frame
14 days after nasal brushing
Secondary Outcome Measure Information:
Title
Nasal potential difference
Description
The nasal potential difference will be evaluated :
in basal,
after infusion of a solution of amiloride,
after infusion of a solution without amiloride chloride,
after infusion of a solution of amiloride and isoproterenol (agonist of cAMP).
Time Frame
14 days after nasal brushing
10. Eligibility
Sex
All
Minimum Age & Unit of Time
18 Years
Accepts Healthy Volunteers
Accepts Healthy Volunteers
Eligibility Criteria
Inclusion Criteria:
For patients with cystic fibrosis and those with atypical form:
• Inclusion at least 30 days after a general or local infection of the upper airways
For controls:
• No history or Sino-pulmonary pathology and negative identification of mutations in the CFTR gene
For all subjects involved in research:
Information and obtaining informed consent of the subjects.
Age ≥ 18 years
affiliation to a social security scheme or of such a regime
Exclusion Criteria:
For all participants :
Taking a per os corticoids or topical corticosteroid treatment in the nose in the month preceding the nasal brushing or measurement of nasal potential difference
ORL surgical history of under 2 months
cauterization of the inferior turbinate of under 2 months
Hypersensitivity to local anesthetics of the amide (such as lidocaine) or with one of the components, including methyl parahydroxybenzoate contained in the excipient.
Porphyria.
Epilepsy not controlled by treatment.
Central Contact Person:
First Name & Middle Initial & Last Name or Official Title & Degree
Virginie Prulière-Escabasse, MD, PhD
Phone
(0)145175597
Ext
+33
Email
virginie.escabasse@chicreteil.fr
First Name & Middle Initial & Last Name or Official Title & Degree
Candy Estevez, CRA
Phone
(0)149813752
Ext
+33
Email
candy.estevez@hmn.aphp.fr
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Virginie Prulière-Escabasse, MD, PhD
Organizational Affiliation
Centre Hospitalier Intercommunal of Creteil
Official's Role
Principal Investigator
Facility Information:
Facility Name
Centre Hospitalier Intercommunal de Créteil
City
Creteil
ZIP/Postal Code
94010
Country
France
Individual Site Status
Recruiting
12. IPD Sharing Statement
Learn more about this trial
Cystic Fibrosis Diagnosis by Analyzing Nasal Brushing
We'll reach out to this number within 24 hrs